

NUTRITIONAL IMMUNITY, ZINC SUFFICIENCY AND COVID-19 MORTALITY IN SOCIALLY SIMILAR EUROPEAN POPULATIONS

Samer Singh, PhD^{1#}; Amita Diwaker, MBBS, MS²; Rakesh K. Singh, PhD³

¹Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

²Department of Obstetrics and Gynecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

³Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi – 221005, India

Address for correspondence: samer.singh10@bhu.ac.in; **ORCID ID:** <https://orcid.org/0000-0002-0921-1686>

ABSTRACT:

The impact of Zinc (Zn) sufficiency/supplementation on COVID-19 mortality and infections remains unknown. During an infection, the levels of free Zinc are reduced as a part of ‘nutritional immunity’ to limit the growth and replication of pathogens and ensuing inflammatory damage. However, considering its key role in immune competence and the widespread deficiency in large sections of different populations (3-54%), prophylactic and therapeutic Zn supplementation has become part of routine prescription even without any evidence for its protective role in COVID-19. Expectedly, multiple trials are ascertaining the positive effect of Zn supplementation on COVID-19 when given in combination with standard of care treatments. However, the trials’ designs seem to lack the power to identify negative effects especially in the currently identified vulnerable groups, e.g., elderly, comorbid (contributing 9 out of 10 deaths; up to >8000-fold higher mortality). When we analyze the COVID-19 data from 23 socially similar European populations with supposedly comparable confounders (population: 522.47 million; experiencing up to >150 fold difference in death rates) and at the matching stage of the pandemic (12 March - 26 June 2020; 1st wave of infections), the populations’ Zn-sufficiency status is found consistently positively correlated with COVID-19 mortality ($r(23)$: 0.7893–0.6849, p -value<0.0003) and infections [$r(23)$:0.8084 to 0.5658; p -value<0.005]. The observed association is contrary to what would be expected if Zn sufficiency was being protective in COVID-19. Thus, controlled trials or retrospective analysis of the adverse event patients’ data seem warranted to correctly guide the practice of Zn supplementation in COVID-19.

Key Words: COVID-19, Nutritional Immunity, Zinc dyshomeostasis, SARS-CoV-2, Micronutrient, Oxidative Stress, Redox, Mortality, Elderly

INTRODUCTION:

Zinc (Zn) is a redox-neutral key micronutrient that plays an important role in immune competence and wellbeing (1-3). Worldwide, the explicit and implicit general recommendations for immune augmentation of the supposed 'Zn-deficient' population components and COVID-19 patients by healthy diet or Zn supplementation are in place. The Zn supplementation is recommended as an adjunctive therapy option by CDC's 'COVID-19 treatment panel guidelines' to supplement the presumed protective role of Zn in infections and other immune and oxidative stress-related conditions/pathologies relevant to COVID-19 (4-7). Lately, a huge surge in the number of articles advocating a role for Zinc supplementation in COVID-19 treatment/management has been observed (keywords '((Zinc) AND (COVID-19)) AND (treatment)' yielded 117 articles in Pubmed on 14 Jan 2021(8). Speculative benefit from Zn supplementation in COVID-19, interpretational and implementational issue with the panel guidelines regarding recommended daily dietary intake due to unavailability of reliable measures of actual deficiency in individuals or the daily dietary intake estimates, combined with the relatively milder side effect of Zn overdose in the majority of the population appeared to have fueled its widespread prescription and over-the-counter purchases. The actual figures of the total increase in Zn supplementation worldwide as a result of the COVID-19 pandemic are not in the public domain but from news articles, it may be surmised that it had already registered a surge by mid-April of 2020 and have steadily increased in different markets/countries since then as per news reports (9-11). However, the clinical evidence supporting any possible beneficial effect of Zinc supplementation or the ecological association studies unequivocally supporting the potential positive impact of Zn sufficiency of the population/individuals on SARS-CoV-2 caused COVID-19 disease are practically nonexistent. The push for Zn supplementation in COVID-19 also seems to stem from the observed negative impact of physiologically 'irrelevant levels' of Zinc in suppressing *in vitro* viral replications in general [REFs 12] and coronaviruses in particular [13]. Globally, Zn deficiency among populations ranges from 3-54% (14). The developed European and North American nations generally have the highest sufficiency while African and Asian nations the least. Its deficiency in populations is widely associated with vulnerability to infectious diseases, chronic immune system disorders, and medical conditions (3-5,7,14,15).

The Zn levels are tightly regulated in the human body and its differential levels are maintained in various organs, tissues, and extracellular milieu including serum through a complex homeostasis mechanism involving multiple regulators and transporters (1, 16-18). Optimal levels are maintained in different tissues, organs as well as immune cells to regulate inflammation and pathogen clearance, reduce reactive oxygen radicals, and affect various bodily processes including lipid metabolism and glucose levels. During infections, Zn levels are reduced in serum and redistributed to tissues and immune cells as a part of 'nutritional immunity' to check pathogens' growth and replication by

withholding Zn availability for its key essential functions (REFs 1, 16, 18, 19). The intracellular Zn reserves are also mobilized and reallocated by elaborate and intricate machinery in the presence of intracellular pathogens in an attempt to reduce the availability of free Zn to limit their survival and diminish replication potential and at the same time signal neighboring cells the presence of pathogens and balance inflammation (REFs in 1, 2, 16, 18, 19). Zn insufficiency is associated with frequent infections and chronic inflammation. In the absence of more accurate measures of Zn deficiency/sufficiency the lower serum levels in conjunction with the presence of associated symptoms of Zn deficiency are used to diagnose pathological deficiency fit for preventive supplementation. However, Zn supplementations are not always without adverse outcome or failures in conditions which are relevant to COVID-19 adverse events and frequently observed in elderly, e.g., sickle cell disease, chronic kidney diseases, cardiovascular diseases (CVD) and coronary heart disease (CHD) (15,20-23).

We hypothesized, if Zn levels would be playing the supposed protective role in the COVID-19 pandemic, the COVID-19 mortality (and infections) would closely but negatively covary with the Zn sufficiency (diet and supplementation) estimates of different socially similar populations. We endeavored to assess the null hypothesis that Zn sufficiency/levels are not associated with COVID-19 mortality in socially similar populations. For this, socially similar European populations at a similar stage of the pandemic, with higher HAQ Index, Life expectancy, Median age (24,25), similar confounders (26-30) but closely graded different Zn sufficiency/deficiency levels (14), and differential COVID-19 impact (24) offer an excellent opportunity to ascertain any potential protective role of Zn levels or its augmentation on COVID-19.

MATERIAL AND METHODS:

Study populations and Zn sufficiency status: The COVID-19 incidences and mortality data (12 March to 26 June 2020) were collected (Table 1) from Worldometer (24). Twenty-three socially similar European populations (Total 522.47 million) with similar confounders (26-30) but different Zn sufficiency/deficiency levels (14), had registered 15.71% cases (1552 thousand cases) and 34.2% deaths (173 thousand deaths) of the total global and more importantly at a similar stage of the pandemic were analyzed for correlation. Pandemic stage-matched data set of European Countries was chosen (12 March to 26 June 2020; 1st wave of Infections) for comparison to minimize the biases that may get introduced in the analysis due to differential timings of the introduction of SARS-CoV-2 (COVID-19) to populations, implementational issues regarding measures in place to minimize spread, reporting lag, etc.

Statistical analysis: All basic statistical analyses including correlation (Pearson's) and regression analysis were performed in Microsoft Excel. COVID-19 mortality and incidence, without applying extra exclusion/inclusion criterion of the risk factors or supposed confounders (e.g., age, sex, age distribution, comorbidities, populations' density, etc.), were assessed for correlation with populations' Zn sufficiency as done previously (26, 29). Interim case fatality ratio (i-CFR) for the populations/groups were calculated as '(reported deaths/reported cases)*100. P-value <0.05 is referred to as statistically significant.

Epidemiological Map display and required color manipulation: Global maps showing country-wise Zn-levels as well as COVID-19 incidence and deaths are adapted from [25]. Color scheme variations in maps were performed using 'Inkscape'.

RESULTS:

When we analyze the COVID-19 incidences and mortality data (12 March to 26 June 2020) of twenty-three socially similar European populations (Total 522.47 million) with similar confounders (26-30), but different Zn sufficiency/deficiency levels (14) accounting for 15.71% cases (1552 thousand cases) and 34.2% deaths (173 thousand deaths) of the total global for correlation (Pearson's) and perform regression analysis without additional exclusion/inclusion criterion of supposed risk factors or confounders (e.g., age, sex, age distribution, comorbidities, populations' density, etc.) some interesting observations were made:

- 1. Globally COVID-19 mortality rates positively covary with Zinc sufficiency levels:** Zinc sufficiency/deficiency levels vary across the globe (Supp. Fig. 1). Generally, differential COVID-19 mortality rates had been observed among countries. The European and North American countries with higher HAQ Index, Life expectancy, Median age (24, 25) coming out as the worst affected. Previously, Trained-immunity (REFs in 26, 27), BCG vaccination (28), vitamin D (29), Zinc deficiency (30) had been associated with reduced COVID-19 mortality using early-stage pandemic data (26-30). They had also attracted criticism for the inappropriateness of the data set, inclusion/exclusion criteria, non-matched pandemic stages among countries, and more importantly the loss of association by mid- or post-peak-of-infections (REFs in 25, 27, 29, 31). Globally the populations were exposed to COVID-19 at different time points and had differences concerning their lifestyles, social structures, preventive measures in place, and access to medical facilities. So, the supposed associations drawn from them could be tenuous due to disparate data sets. To arrive at more dependable conclusions, when pandemic phase-matched (Supp. Fig. 2), populations with comparable confounders (26,28,29,31) were analyzed the COVID-19 mortality

rate in socially similar populations (Boxed North America and European Union NA and EU) were found to strongly associate with their Zinc sufficiency (Supp. Fig 1; time-series graphics available at reference 25). Incidentally, European, North American, and South American countries reporting high mortality have been the high Zinc sufficiency countries.

2. Zinc sufficiency strongly and significantly correlated with COVID-19 mortality in socially

similar countries: The Zinc sufficiency in twenty-three socially similar European populations (Fig 1A, Table 1) positively associated with COVID-19 mortality and infection rates (Fig. 1B-C). The mortality and infections covaried exponentially with Zn sufficiency (Fig. 1D-E). Above >92.5% Zn sufficiency, the populations experienced up to 9X higher deaths (Fig. 1D). Pearson's correlation for the most synchronized period of infections and response (26 April to 26 June, Supp. Fig. 2) was strong [Table 2, Deaths per million: $r(23)= 0.7455-0.6849$, $p<0.0003$; Cases per million: $r(23)= 0.8084-0.7629$, $p<0.00002$]. Even the division of countries using >93.7% sufficiency cutoff, indicated high mortality (5.79 to 2.66X) and incidences (4.5 to 2.3-fold) in High Zn sufficiency populations (n=12) as compared to Low sufficiency (n=11). Some of the outlier populations that fared extremely well and displayed quite low mortality among the higher Zn sufficiency countries, e.g., Iceland, Finland, Norway, Denmark, also happen to have higher levels of 'trained immunity' and serum 'vitamin D' levels - two other protective variables proposed earlier (26, 27, 29).

3. Higher Zn sufficient socially similar countries/populations consistently reported higher

COVID-19 case fatality rates (CFRs) and incidence rates: The CFRs of different sufficiency population groups, i.e., high (>93.7%, 12 countries) vs low (<93.7% 11 countries) had been essentially different and showing decline post-peak-of-infections, i.e, 12 May (Fig. 1F) possibly indicative of a more uniform reporting in later stages or progressive increase in protected population but the relative change in the CFR decrease had been lower for the higher sufficiency countries and the gap had consistently increased during the period (about 16% on 26 June that become 30 % by 26 Aug 2020) (Fig. 1G).

DISCUSSION AND CONCLUSION:

Overall a general positive correlation of COVID-19 mortality and cases with Zn sufficiency levels was observed during the 1st wave of infections, which sustained till the flattening of the curves. Nevertheless, comparison of socially similar' populations/countries at similar phase/stages of the pandemic with comparable potential confounders, closely graded Zn sufficiency levels of study populations that globally accounted for 34.2% mortality (173 thousand deaths) gives confidence to the

observations made. The surprisingly strong association between Zn sufficiency of socially similar study populations with COVID-19 mortality and incidences for the whole study duration even stronger than those being hotly discussed, debated and evaluated in clinical trials (28, 29, 31), warrants thorough investigation.

Zinc bioavailability reduction during infections has been recognized as a routine part of 'nutritional immunity' and has been comprehensively reviewed (1, 16, 19, 32). The drop in serum Zn levels is primarily attributed to the proinflammatory cytokine-mediated alteration in the expression of hepatic Zn transporter proteins during the acute phase of inflammation through squelching of serum Zn coming from the diet (33). The cell-mediated Zn restrictions, reallocation, and mobilization (primarily mediated by ZIP family of transporters, e.g., ZIP8 in *Mycobacterium tuberculosis* (34), as well as extracellular Zn sequestration (primarily mediated by S100 family of proteins, e.g., calprotectin, psoriasin, calgranulin, etc.) is supposed to be part of an elaborate intricate immune mechanism to both starve of and/or intoxicate pathogen with this key element as per differential need (REFs in 1, 2, 18, 19). Calprotectin, an S100A8/S100A9 heterodimer, seems to be a key player in immune regulation through its ability to chelate Zn and other metal ions (1, 35) and also serve as a damage-associated molecular pattern and a ligand for Toll-like receptor 4 (TLR4) (36). It can account for >40% of cytoplasmic proteins in neutrophils during infection (37). *In vitro* studies have shown an important role of calprotectin in inhibiting the growth of the pathogens while the supplementation of Zn has been shown to revert the calprotectin-mediated growth inhibition (38-40). Here the Zn starvation strategy could primarily interfere with the Zn-dependent infection process and replication while the intoxication could help the generation of ROS in a localized manner for effective pathogen incapacitation and elimination (REFs in 1, 2, 32). The existing pieces of evidence point to the mobilization of Zn during infection as a measure to not only limit its availability to invading pathogens but also prime immune cells to intoxicate pathogens.

Systematic reviews of Zinc supplementation studies had shown a significant reduction of diarrhea incidents and the associated deaths in Zinc deficient children (REFs in 41-43). It now forms a part of global diarrhea control measures. Several published studies using a small group of individuals/patients do indicate a benefit of Zn supplementation in other diseases as well including pneumonia and lower respiratory tract infections relevant to COVID-19 (REFs in 41). However, the systematic reviews and meta-analysis of the previous studies could not support the supposed positive influence of Zn supplementation on the prevention and treatment of different diseases when Zn sufficient individuals were also included in studies (REFs in 41,43). Though Zn sufficiency promotes the well-being and integrity of respiratory cells during lung inflammation and protects them from injury arising from respiratory tract infections (RTI) and decrease the incidence of infections by regulating immune functions and response (44), the ability of zinc supplementation to help reduce the infection, severity or

treatment of lower RTI (a comorbid condition in > 50% COVID-19 deaths) has not been unequivocally supported in different Zn sufficiency patient populations. A Cochrane Systematic review that summarized 73 studies of Zn supplementation performed in Zn-sufficient and deficient children (low and middle-income countries) up to the age of 12 years did not find evidence for the reduction in RTI (prevention) but indicated a negative effect on Cu status (42). However, when the same set of studies additionally considered the Iron supplementation status a reduction in death risk ratio from RTI was observed as per the studies summarized in the WHO document available in e-Library of Evidence for Nutrition Actions (eLENA) [43]. Similarly, as per studies summarized in WHO guidelines for tuberculosis patients, Zinc supplementation does not have desired beneficial effects on tuberculosis patients who chronically have lower circulating Zn levels (45). A more recently updated meta-analysis of Zn micronutrient supplementation also could not find augmentation of the tuberculosis therapy outcomes as assessed at different time points (e.g., sputum-culture or sputum-smear positivity, chest x-ray clearance; death in HIV positive patients) (46). The findings of a ZINC trial, recently reported in JAMA, that evaluated the effect of Zn supplementation on survival of HIV patients who have been also hit hard by the COVID-19 pandemic, were discerning (47). A detrimental effect of Zn supplementation on the overall survival of study participants was observed. The study using a cohort of HIV-positive alcoholic veterans endeavored to ascertain the effect of zinc supplementation on markers of mortality, the risk of cardiovascular disease, the levels of inflammation and associated microbial translocation and HIV disease progression, and finally concluded that among survivors the Zn supplementation did not affect/improve the markers investigated in the study based upon its analysis of the 69% participants who completed the 18-month study period. Surprisingly, a closer look at the cause of dropouts or the deceased of the study provided in the supplementary table (eTable. 'Causes of Death in the ZINC Trial by Randomized Group'), provides a glaringly different narrative. It highlights a potentially serious detrimental/negative impact of Zn supplementation on a section of the HIV-infected cohort. The Zinc supplemented group in comparison to the control group had observed almost two-fold higher all-cause mortality, *i.e.*, 21/126 vs 12/128. If we remove the unknown cause of deaths from both groups the deaths were about 3 times more frequent in the Zn supplemented group (19/126 vs 7/128). Distribution of deaths in the Zn supplemented vs control group concerning COVID-19 relevant conditions (23) was more surprising, e.g., HIV-related deaths: 7/21 vs 2/12; overdose-related deaths 4/21 vs 1/12; deaths from pneumonia: 3/21 vs 0/12; deaths from suicide: 2/21 vs 0/12; deaths from Thromboembolism: 1/21 vs 0/12.

Two notions that are supposedly further contributing to the increase in Zinc supplementation for COVID-19 are, a) Zinc can block viral replication, b) patients reporting COVID-19 symptoms have lower Zinc levels. It must be remembered here that the free Zinc levels required to achieve viral replication

inhibition *in vivo* are not possible without killing the host (12). During infections and fever as a result of the natural ‘nutritional immunity’ response, the availability of cellular as well as the systemic Zn (from circulation) is reduced to impede the growth of pathogens (1, 2, 19, 48). The redistribution of Zn from circulation is part of a mechanism to limit the oxidative damage to peripheral tissues, away from circulatory or other vital systems during infections, which may experience a transient or sustained localized increase of oxidative radicals as a part of an immune response.

The variable(s) responsible for the observed association between Zn sufficiency and COVID-19 mortality remain undefined. We speculate that the increased mortality observed in high Zn sufficiency populations could be contributed by the existing underlying conditions of altered genetic composition, physiology, response to Zn supplementations/modulation in certain sections of the population [15-22,49]. It would be making them prone to display characteristic COVID-19 adverse illness as a result of increased oxygen radical generation or diminished oxidative stress handling system due to their physiologies’ propensity to promote the pro-oxidant role of Zn on supplementation (2). It may be pertinent here to mention that Zinc overdoses would have the potential to negatively affect the activity of different Zn dependent antioxidative system components leading to oxidative stress and damage, e.g., the R213G polymorphism in superoxide dismutase 3 (SOD3), a key member of the extracellular reactive oxygen species (ROS) neutralization system, found in 2-6 % of the population makes them prone to oxidative stress promoted hypertension and increased risk of cardiovascular infarctions and thrombosis (REFs OMIM #185490 ‘SUPEROXIDE DISMUTASE 3; SOD3’ <https://www.omim.org/entry/185490>; additional info at <http://www.wikigenes.org/e/gene/e/6649.html>) - the conditions frequently observed in COVID-19 adverse events (50). Moreover, the Zn overdose is not uncommon in the highly impacted aged population of the developed countries that are more receptive to supplementation with or without a prescription (51).

Recently published metanalysis of drugs being prescribed worldwide as a standard of care and the investigational drugs being evaluated in clinical trials for COVID-19 treatment, starkly indicate that the most promising drug for alleviating COVID-19 symptoms and decreasing the mortality had been such corticosteroids alone (52,53) that also suppress the Zn levels (54-56) along with increasing levels of oxidative damage protecting metallothioneins (57-58). A similar increase in metallothionein levels had been reported for 1,25-dihydroxy vitamin D3 (59) as well, another potential protective variable for COVID-19 (29, 60). This serum Zn level suppression property of the select corticosteroids is also shared by steroid hormone estradiols which are naturally higher in females and youngs – two broad groups that had also consistently displayed lower vulnerability to COVID-19 adverse events (23). Whether these occurrences are coincidences or have mechanistic underpinnings only future investigations would reveal.

In conclusion, the observations presented, though circumstantial, underscore the need to revisit existing Zn supplementation guidelines for COVID-19 patients. Exploratory studies should be undertaken to correctly identify different underlying comorbid conditions that could make certain Zn supplemented individuals prone to COVID-19 mortality. The outcomes could help devise more thorough and comprehensive Zn supplementation practices for minimizing COVID-19 mortality among the vulnerable.

ACKNOWLEDGEMENTS/ DISCLOSURES

Funding: No specific source of funding was utilized for the current study. However, SS acknowledges the funding support to his laboratory from the Institute of Eminence (IoE) seed grant, Banaras Hindu University.

Conflict of interest: There is no conflict of interest to disclose.

Ethical statement: The study is compliant with ethical standards. Considering the design of the study no human or animal rights were infringed upon.

Informed consent: Considering the design of the study no informed consent was necessary.

REFERENCES:

1. Lonergan ZR, Skaar EP. Nutrient Zinc at the Host-Pathogen Interface. *Trends in Biochemical Sciences* 2019. <https://doi.org/10.1016/j.tibs.2019.06.010>
2. Maret W. The redox biology of redox-inert zinc ions. *Free Radical Biology & Medicine*. 2019;134:311-326. DOI: 10.1016/j.freeradbiomed.2019.01.006.
3. Prasad, A. S. (2013). Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease. *Advances in Nutrition*, 4(2), 176-190. Available at: <https://academic.oup.com/advances/article/4/2/176/4591626>
4. Christianne de Faria Coelho-Ravagnani, Flavia Campos Corgosinho, Fabiane La Flor Ziegler Sanches, Carla Marques Maia Prado, Alessandro Laviano, João Felipe Mota, Dietary recommendations during the COVID-19 pandemic, *Nutrition Reviews*, , nuaa067, <https://doi.org/10.1093/nutrit/nuaa067>
5. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. *Nutrients*. 2020;12(4). :1181. Doi: 10.3390/nu12041181
6. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [12 January 2021].
7. Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. *Front Immunol*. 2020; 11:1712. <https://doi.org/10.3389/fimmu.2020.01712>
8. <https://pubmed.ncbi.nlm.nih.gov/?term=%28%28Zinc%29+AND+%28COVID-19%29%29+AND+%28treatment%29&sort=>
9. <https://www.newhope.com/market-data-and-analysis/market-overview-2020-supplement-sales-shift-changing-trends-and-refocused> [Accessed 12 Jan 2021]
10. <https://www.kktv.com/content/news/Zinc-sales-skyrocket-at-supplement-manufacturing-company-amid-pandemic-569900931.html> [Accessed 12 Jan 2021]
11. https://timesofindia.indiatimes.com/business/india-business/multivitamin-tops-drug-sales-for-1st-time-in-oct/articleshow/79768560.cms [Accessed 12 Jan 2021]
12. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. *Adv Nutr*. 2019 Jul 1;10(4):696-710. Doi: 10.1093/advances/nmz013. PMID: 31305906; PMCID: PMC6628855.
13. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PloS Pathog*. 2010;6(11):e1001176
14. Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. *PloS one*, 7(11): e50568
15. Prasad, AS, Brewer, GJ, Schoomaker, EB, et al. Hypocupremia Induced by Zinc Therapy in Adults. *JAMA*. 1978;240(20):2166-2168. Doi:10.1001/jama.1978.03290200044019
16. Bonaventura P, Benedetti G, Albarède F, Miossec P. Zinc and its role in immunity and inflammation. *Autoimmun Rev*. 2015 Apr;14(4):277-85. doi: 10.1016/j.autrev.2014.11.008.
17. Kimura, T. and Kambe, T. (2016) The functions of metallothionein and ZIP and ZnT transporters: an overview and perspective. *Int. J. Mol. Sci*. 17, 336
18. Rink, L. and Haase, H. (2007) Zinc homeostasis and immunity. *Trends Immunol*. 28, 1–4

19. Hood MI, Skaar EP. Nutritional immunity: transition metals at the pathogen–host interface. *Nat Rev Microbiol.* 2012; 10: 525-537. doi:10.1038/nrmicro2836
20. Nishime K, Kondo M, Saito K, Miyawaki H, Nakagawa T. Zinc Burden Evokes Copper Deficiency in the Hypoalbuminemic Hemodialysis Patients. *Nutrients.* 2020 Feb 23;12(2):577. Doi: 10.3390/nu12020577. PMID: 32102170; PMCID: PMC7071503.
21. Milton AH, Vashum KP, McEvoy M, Hussain S, McElduff P, Byles J, Attia J. Prospective Study of Dietary Zinc Intake and Risk of Cardiovascular Disease in Women. *Nutrients* 2018, 10, 38; doi:10.3390/nu10010038
22. Qu X, Yang H, Yu Z, Jia B, Qiao H, Zheng Y, Dai K. Serum zinc levels and multiple health outcomes: Implications for zinc-based biomaterials. *Bioact Mater.* 2020 Mar 31;5(2):410-422. Doi: 10.1016/j.bioactmat.2020.03.006
23. CDC. Your Health: People with Certain Medical Conditions. Centers for Disease Control and Prevention (CDC), U.S. Department of Health & Human Services, 2020 (Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases) (<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>; Updated 29 December 2020)
24. Worldometer. COVID-19 Coronavirus Pandemic. <https://www.worldometers.info/coronavirus/>
25. Max Roser, Hannah Ritchie, Esteban Ortiz-Ospina and Joe Hasell (2020) – “Coronavirus Pandemic (COVID-19)”. Published online at OurWorldInData.org. Retrieved from: ‘<https://ourworldindata.org/coronavirus>’ [Online Resource]
26. Singh S, Maurya RP, Singh RK. “Trained immunity” from Mycobacterium spp. Exposure or BCG vaccination and COVID-19 outcomes. *PLoS Pathog.* 2020 Oct 29;16(10):e1008969. Doi: 10.1371/journal.ppat.1008969. PMID: 33119725.
27. Singh S. BCG Vaccines May Not Reduce Covid-19 Mortality Rates. medRxiv2020.04.11.20062232. <https://doi.org/10.1101/2020.04.11.20062232>
28. Escobara LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *PNAS* 2020; 117: 17720-17726; www.pnas.org/cgi/doi/10.1073/pnas.2008410117
29. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. *Aging Clin Exp Res* 2020; 32:1609–1612 DOI: 10.1007/s40520-020-01619-8
30. Singh S. Covariation of Zinc Deficiency with COVID-19 Infections and Mortality in European Countries: Is Zinc Deficiency a Risk Factor for COVID-19? medRxiv; 2020. DOI: 10.1101/2020.06.12.20105676.
31. Arlehamna CSL, Settea A, Peters B. Lack of evidence for BCG vaccine protection from severe COVID-19. *PNAS* 2020; 117: 25203–25204; www.pnas.org/cgi/doi/10.1073/pnas.2016733117
32. Palmer, L.D. and Skaar, E.P. (2016) Transition metals and virulence in bacteria. *Annu. Rev. Genet.* 50, 67–91
33. Aydemir, T.B. et al. (2012) Zinc transporter ZIP14 functions in hepatic zinc, iron and glucose homeostasis during the innate immune response (endotoxemia). *PLoS One* 7, e48679
34. Pyle CJ, Azad AK, Papp AC, Sadee W, Knoell DL, Schlesinger LS. Elemental Ingredients in the Macrophage Cocktail: Role of ZIP8 in Host Response to Mycobacterium tuberculosis. *Int J Mol Sci.* 2017 Nov 9;18(11):2375. doi: 10.3390/ijms18112375.

35. Hunter MJ, Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. *J Biol Chem*. 1998 May 15;273(20):12427-35. doi: 10.1074/jbc.273.20.12427.
36. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. *Nat Med*. 2007 Sep;13(9):1042-9. doi: 10.1038/nm1638.
37. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. *Biol Pharm Bull*. 2003 Jun;26(6):753-60. doi: 10.1248/bpb.26.753
38. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, et al. Metal chelation and inhibition of bacterial growth in tissue abscesses. *Science*. 2008;319(5865):962-5. doi: 10.1126/science.1152449.
39. Besold AN, Gilston BA, Radin JN, Ramsomair C, Culbertson EM, Li CX, et al. Role of Calprotectin in Withholding Zinc and Copper from *Candida albicans*. *Infect Immun*. 2018 Jan 22;86(2):e00779-17. doi: 10.1128/IAI.00779-17.
40. Wang J, Lonergan ZR, Gonzalez-Gutierrez G, Nairn BL, Maxwell CN, Zhang Y, et al. Multi-metal Restriction by Calprotectin Impacts De Novo Flavin Biosynthesis in *Acinetobacter baumannii*. *Cell Chem Biol*. 2019 May 16;26(5):745-755.e7. doi: 10.1016/j.chembiol.2019.02.011.
41. Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. *Nutrients*. 2020 Jan 16;12(1):236. doi: 10.3390/nu12010236.
42. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, et al. Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. *Cochrane Database Syst Rev* 2014, Cd009384.
43. World Health Organization. Zinc supplementation in children with respiratory infections e-Library of Evidence for Nutrition Actions (eLENA). World Health Organization (updated 11 February 2019) (https://www.who.int/elena/titles/zinc_pneumonia_children/en/; Accessed on 12 October 2020)
44. Bao S, Knoell DL. Zinc modulates airway epithelium susceptibility to death receptor- mediated apoptosis. *American Journal of Physiology – Lung Cellular and Molecular Physiology*. 2006; 290:L433–L441.
45. World Health Organization. Guideline: Nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013. ISBN: 978 92 4 150641 0 (https://apps.who.int/iris/bitstream/handle/10665/94836/9789241506410_eng.pdf;jsessionid=BE E74AC32E3B6835C757E6787332B883?sequence=1
https://www.who.int/nutrition/publications/guidelines/nutcare_support_patients_with_tb/en/)
46. Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. *Cochrane Database of Systematic Reviews* 2016, Issue 6. Art. No.: CD006086. DOI: 10.1002/14651858.CD006086.pub4. [Accessed 14 January 2021]
47. Freiberg MS, Cheng DM, Gnatienco N, et al. Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial. *JAMA Netw Open*. 2020;3(5):e204330. Doi:10.1001/jamanetworkopen.2020.4330

48. Brown KH. Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. *Am J Clin Nutr* 1998;68(suppl):425S–9S.
49. Cabrera AJR. Zinc, aging, and immunosenescence: an overview. *Pathobiology of Aging & Age-related Diseases* 2015, 5: 25592 – <http://dx.doi.org/10.3402/pba.v5.25592>
50. Khawaja SA, Mohan P, Jabbour R, et al. COVID-19 and its impact on the cardiovascular system. *Open Heart* 2021;8:e001472. doi: 10.1136/openhrt-2020-001472
51. Agnew UM, Slesinger TL. Zinc Toxicity. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554548/> [Updated 2020 May 7].
52. Rochwerg B, Siemieniuk R A, Agoritsas T, Lamontagne F, Askie L, Lytvyn L et al. A living WHO guideline on drugs for covid-19. *BMJ* 2020; 370 :m3379 doi:10.1136/bmj.m3379 (last updated 31 March 2021; ‘Therapeutics and COVID-19: living guideline’ available at <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1>)
53. Siemieniuk R A, Bartoszko J J, Ge L, Zeraatkar D, Izcovich A, Kum E et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ* 2020; 370 :m2980 doi:10.1136/bmj.m2980 (last updated 06 April 2021)
54. Briggs MH, Briggs M, Austin J. Effects of steroid pharmaceuticals on plasma zinc. *Nature*. 1971 Aug 13;232(5311):480-1. doi: 10.1038/232480a0. PMID: 4937210.
55. Yunice AA, Czerwinski AW, Lindeman RD. Influence of synthetic corticosteroids on plasma zinc and copper levels in humans. *Am J Med Sci*. 1981 Sep-Oct;282(2):68-74. doi: 10.1097/00000441-198109000-00003. PMID: 7325187.
56. Ellul-Micallef R, Galdes A, Fenech FF. Serum zinc levels in corticosteroid-treated asthmatic patients. *Postgrad Med J*. 1976;52(605):148-150. doi:10.1136/pgmj.52.605.148
57. Karin M, and Herschman HR. Induction of Metallothionein in HeLa Cells by Dexamethasone and Zinc. *Eur J Biochem*, 1981; 113: 267-272. <https://doi.org/10.1111/j.1432-1033.1981.tb05062.x>
58. Kobayashi S, Okada T, Kimura M. Effects of dexamethasone on metallothionein induction by Zn, Cu, and Cd in Chang liver cells. *Chem Biol Interact*. 1985 Nov;55(3):347-56. doi: 10.1016/s0009-2797(85)80141-1
59. Hanada K, Sawamura D, Nakano H, Hashimoto I. Possible role of 1,25-dihydroxyvitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes. *J Dermatol Sci*. 1995 May;9(3):203-8. doi: 10.1016/0923-1811(94)00378-r.
60. Singh S, Singh S, Kaur R, Diwaker A, Kishore D. How Strong is the Epidemiological Evidence for a Role of Vitamin D Levels on COVID-19 Infections and Mortality? *J Sci. Res.* 2021;65,(1):159-165. <http://dx.doi.org/10.37398/JSR.2021.650120>

Figure Legends:

Fig. 1. Zinc sufficiency of the socially similar European populations correlated with COVID-19 mortality. Study populations: **(A)** Zn sufficiency estimates, **(B)** and **(C)** deaths and cases/million (26th April). [Note: Global maps (25) displayed color scheme variations performed using 'Inkscape']. Deaths **(D)** and cases **(E)** per million population positively correlated with their Zn sufficiency levels. **(F)** For the group of countries with different Zn sufficiency the interim case fatality ratio [i-CFR or Avg. CFR' = (reported deaths/ reported cases)*100] remained different throughout the period after peaking in May 2020. **(G)** Fold change in the relative CFR for high sufficiency (Suff.) with respect to low suff. countries has been registering a steady increase while the gap for cases has kept shrinking.

Table 1. COVID-19 incidences and mortality in socially similar European populations

Table 2. Correlation Analysis of COVID-19 mortality and incidence with Zinc sufficiency of populations. Correlation analysis for the most synchronized period of infections and response in twenty-three socially similar European countries (highlighted yellow period – covers the rise and flattening of infections/mortality rate (see Supp. Fig. 2). P-value <0.05 is referred to as statistically significant.

Supplementary Figure 1. Globally, Zinc sufficiency levels are positively associated with COVID-19 impact on populations. **(A)** Zinc levels vary across countries. European (EU) and North American (NA) countries (red box) with higher development index more diverse diet and food fortification had higher Zn sufficiency. **(B)** The mortality per million population in socially similar EU and NA countries and similar stage of pandemic strongly covary (higher sufficiency- higher deaths). *For analysis of European nations see the main manuscript.* **(C)** Cases per million across countries. Images adapted from refs. 14, 25

Supplementary Figure 2. The waves of COVID-19 deaths (8 out of 10 were elderly) **(A)** as it passed through countries under study and incidence rates (majority younger – without dysregulated Zn homeostasis) **(B)**.




Fig. 1. Zinc sufficiency of the socially similar European populations correlated with COVID-19 mortality. Study populations: **(A)** Zn sufficiency estimates, **(B)** and **(C)** deaths and cases/million (26th April). [Note: Global maps (25) displayed color scheme variations performed using 'Inkscape']. Deaths **(D)** and cases **(E)** per million population positively correlated with their Zn sufficiency levels. **(F)** For the group of countries with different Zn sufficiency the interim case fatality ratio [i-CFR or Avg. CFR' = (reported deaths/ reported cases)*100] remained different throughout the period after peaking in May 2020. **(G)** Fold change in the relative CFR for high sufficiency (Suff.) with respect to low suff. countries has been registering a steady increase while the gap for cases has kept shrinking.

Table 1. COVID-19 incidences and mortality in socially similar European populations

COUNTRIES	2020 Mar		2020 Apr		2020 May		2020 Jun		2020 Jul		2020 Aug		Population	3% Zn Def. (2005)	3% Zn Suff. (2005)				
	CpM	DpM	CpM	DpM	CpM	DpM	CpM	DpM	CpM	DpM									
Iceland	342.51	0.00	2347.79	5.85	4979.54	23.42	5245.93	29.27	5272.28	29.27	5281.06	29.27	5272.90	29.27	341598	3.10	96.90		
France	44.04	0.93	446.50	25.97	1461.06	220.22	1907.82	349.69	2147.53	412.99	2229.12	436.54	2393.48	449.47	2495.31	455.66	65296963	3.90	96.10
Ireland	14.15	0.20	367.73	3.84	1950.46	67.52	3892.64	218.94	4697.25	300.01	4999.08	325.68	5103.19	343.88	5136.34	348.93	4946514	4.00	96.00
Finland	19.67	0.00	172.86	0.90	536.62	10.10	825.68	34.28	1083.16	49.62	1195.93	56.30	1276.23	58.64	1297.52	59.18	5542120	4.60	95.40
UK	7.89	0.13	155.54	12.92	1123.82	180.71	2038.02	352.76	3019.69	472.95	3536.57	532.41	3906.24	577.36	4125.05	592.38	67943420	4.60	95.40
Switzerland	100.18	0.81	1363.11	22.16	2933.15	127.64	3353.93	185.81	3506.16	215.47	3550.13	221.01	3584.98	223.66	3633.80	226.43	8664751	4.90	95.10
Netherlands	35.82	0.29	433.52	25.32	1492.73	159.68	2207.86	261.07	2507.67	321.45	2659.00	341.64	2827.19	353.13	2917.27	356.05	17141028	5.00	95.00
Spain	665.43	1.84	3118.24	93.35	4667.48	368.05	5243.71	495.96	5493.08	574.36	5622.58	595.47	5738.28	604.71	5819.68	606.06	46757733	5.40	94.60
Italy	250.17	16.87	1333.08	136.33	2586.60	330.19	3269.98	441.89	3659.54	512.71	3814.12	546.69	3909.39	567.70	3970.11	576.73	60447245	5.80	94.20
Sweden	76.27	0.10	296.36	13.26	1079.30	134.03	1865.89	253.13	2775.15	369.85	3523.17	438.21	4982.21	500.53	6450.65	536.53	10109375	6.10	93.90
Norway ⁵	147.38	0.18	621.22	2.58	1202.10	23.58	1386.69	37.03	1502.76	42.00	1544.40	43.29	1588.06	44.58	1627.11	45.87	5428015	6.20	93.80
Denmark ⁵	116.30	0.00	323.87	7.07	1065.31	47.11	1479.60	72.82	1827.45	90.93	1971.87	97.14	2072.12	102.49	2187.04	104.22	5795502	6.20	93.80
Portugal	7.65	0.00	347.73	5.89	1627.29	49.45	2324.22	88.60	2738.77	114.11	3042.34	131.67	3549.91	147.67	4009.69	152.57	10191814	6.30	93.70
Belgium	34.40	0.34	537.60	41.30	2556.27	370.16	3977.84	627.10	4637.01	753.16	4953.97	797.05	5157.80	821.97	5268.77	829.30	11597764	6.80	93.20
Lithuania	1.102	0	100.651	1.469	386.807	8.449	523.824	15.061	545.496	18.367	600.597	23.142	643.576	27.183	663.412	28.652	2725537	7.5	92.50
Hungary	1.66	0.00	27.03	1.04	146.02	10.25	258.90	28.17	343.09	44.01	390.52	51.68	419.73	57.48	427.39	59.86	9656316	8.40	91.60
Germany	32.75	0.07	524.15	3.19	1525.21	36.05	1882.08	71.29	2065.81	92.31	2162.64	101.38	2233.77	105.73	2319.04	107.67	83827321	9.00	91.00
Poland	0.819	0	27.77	0.37	167.941	5.496	297.86	13.845	431.373	21.429	571.544	26.607	745.139	32.103	875.085	37.308	37850425	10.3	89.70
Estonia	20.35	0.00	405.52	0.75	986.67	18.84	1238.43	36.93	1316.07	45.98	1382.40	47.49	1484.91	47.49	1496.97	47.49	1326860	10.50	89.50
Czechia	10.92	0.00	189.32	0.84	561.32	12.88	693.23	20.54	769.50	26.42	846.98	29.59	929.87	30.71	1032.56	32.39	10712210	11.00	89.00
Ukraine	0.00	0.00	2.584	0.091	57.416	1.669	185.783	4.596	357.801	9.329	485.78	14.245	664.704	19.527	914.808	24.398	43757273	11.4	88.60
Bulgaria	1.007	0.144	34.828	0.432	95.129	4.03	179.465	7.915	286.395	13.384	350.15	18.709	444.128	24.178	634.387	30.367	6953085	15.3	84.70
Slovakia	3.85	0.00	41.39	0.00	135.90	0.37	252.56	3.30	268.31	4.94	277.10	5.13	282.41	5.13	300.91	5.13	5460073	16.30	83.70

Average (High Zn suff. ≥93.8 % countries(12))	151.65	1.78	914.99	29.13	2089.85	141.02	2726.48	227.72	3124.31	282.64	3327.25	305.31	3555.93	321.29	3748.98	328.11		4.98	95.02
STDEV	191.10	4.78	952.49	41.97	1443.75	118.60	1472.46	162.11	1448.39	195.01	1460.40	210.62	1525.52	222.57	1690.16	227.95	298414264	1.00	1.00

Average (Low Zn suff. <93.8% (11))	10.41	0.05	203.51	5.03	749.63	47.06	1074.02	83.40	1250.87	103.95	1369.46	113.34	1505.09	119.92	1631.18	123.19		10.25	89.75
STDEV	12.95	0.11	210.70	12.15	827.40	108.24	1210.52	182.42	1388.03	218.12	1474.75	230.05	1555.97	236.58	1611.60	237.97	224058498	3.23	3.23

Note:
 1. Countries socially similar with supposedly comparable confounders ref 1,2.)
 2. CpM: Cases per million; DpM: Deaths per million; Mar: March; Apr: April; Jun: June; Jul: July; Aug: August. 2020
 3. Zn deficiency (def.; Sufficiency (suff. = 100-Def.) estimates for populations based upon overall intake (e.g., food, fortified articles) and stunting prevalence from Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PLoS one, 7(11) : e50568. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510072/>
 4. STDEV: Standard deviation

5. If these countries also included in LOW Suff. group the mortality and incidence rate gap with HIGH Suff. countries will increase further. However for the sake of keeping groups almost equal sized, we preferred to err to show lesser difference between the two group of countries, as we still do not have the cause and effect evidence for the association observed.

CORRELATION ANALYSIS								
Data-Date	12 Mar	26 Mar	12 Apr	26 Apr	12 May	26 May	12 Jun	26 Jun
Average Deaths/Million Pop. ± STDEV	0.95 ± 3.50	17.61 ± 33.16	96.08 ± 121.08	158.70 ± 183.58	197.18 ± 221.29	213.49 ± 236.32	224.98 ± 246.55	230.11 ± 250.35
DEATHS/Million(Log) vs Zn SUFF. - Correlation $r(23)$:	0.3731	0.7893	0.7642	0.7455	0.7213	0.7099	0.6989	0.6849
p-value	0.0795	7.6E-06	2.19E-05	4.5E-05	0.0001	0.0001	0.0002	0.0003
Average Cases/million Pop. ± STDEV	84.10 ± 153.42	574.71 ± 778.36	1448.88 ± 1349.80	1936.17 ± 1569.23	2228.32 ± 1685.30	2390.92 ± 1747.82	2575.09 ± 1833.38	2736.12 ± 1943.94
CASES/Million (Log) vs Zn SUFF. - Correlation $r(23)$:	0.5658	0.6513	0.7681	0.7906	0.8067	0.8084	0.7966	0.7629
p-value	0.0049	0.0008	1.88E-05	7.1E-06	3.33E-06	3.05E-06	5.42E-06	2.3E-05

Table 2. Correlation Analysis of COVID-19 mortality and incidence with Zinc sufficiency of populations. Correlation analysis for the most synchronized period of infections and response in twenty-three socially similar European countries (highlighted yellow period – covers the rise and flattening of infections/mortality rate (see Supp. Fig. 2). P-value <0.05 is referred to as statistically significant.